A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma

PURPOSE: Immune checkpoint inhibitor and VEGFR inhibitor combinations are effective treatments for patients with metastatic renal cell carcinoma (mRCC). This phase I/II clinical trial evaluated the safety and efficacy of pembrolizumab and cabozantinib in patients with mRCC. EXPERIMENTAL DESIGN: Elig...

Descripción completa

Detalles Bibliográficos
Autores principales: Kessler, Elizabeth R., Callihan, Eryn, Hu, Junxiao, Eule, Corbin, Srivastava, Geetika, Kemme, Douglas J., Iruku, Praveena, Rana, Vishal, Moore, James, Schuster, Steven R., Amirault, Mali, Flaig, Thomas W., Lam, Elaine T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249509/
https://www.ncbi.nlm.nih.gov/pubmed/37377613
http://dx.doi.org/10.1158/2767-9764.CRC-23-0060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249509/
https://www.ncbi.nlm.nih.gov/pubmed/37377613
http://dx.doi.org/10.1158/2767-9764.CRC-23-0060

Ejemplares similares